Literature DB >> 28581028

Measuring the Value of Pharmacogenomics Evidence.

G P Patrinos1,2, C Mitropoulou3.   

Abstract

In recent years, there is a growing need to measure the value of pharmacogenomics testing so that policymakers are well informed to decide about adopting and reimbursing pharmacogenomics testing, prioritizing pharmacogenomics research and development, and encouraging the application of companion diagnostics. Presently, there are limited economic evaluation studies of genome-guided treatment modalities that would allow decision-makers to comparatively assess the value and clinical utility of such interventions.
© 2017 ASCPT.

Mesh：

Year:  2017        PMID： 28581028     DOI： 10.1002/cpt.743

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  6 in total

1.  Strategies to improve pharmacogenomic-guided treatment options for patients with β-hemoglobinopathies.

Authors:  George P Patrinos; David H K Chui; Ross C Hardison; Martin H Steinberg
Journal:  Expert Rev Hematol       Date:  2021-09-08       Impact factor: 2.819

Review 2.  Precision Medicine: An Optimal Approach to Patient Care in Renal Cell Carcinoma.

Authors:  Revati Sharma; George Kannourakis; Prashanth Prithviraj; Nuzhat Ahmed
Journal:  Front Med (Lausanne)       Date:  2022-06-14

3.  Pharmacogenomics decision support in the U-PGx project: Results and advice from clinical implementation across seven European countries.

Authors:  Kathrin Blagec; Jesse J Swen; Rudolf Koopmann; Ka-Chun Cheung; Mandy Crommentuijn-van Rhenen; Inge Holsappel; Lidija Konta; Simon Ott; Daniela Steinberger; Hong Xu; Erika Cecchin; Vita Dolžan; Cristina Lucía Dávila-Fajardo; George P Patrinos; Gere Sunder-Plassmann; Richard M Turner; Munir Pirmohamed; Henk-Jan Guchelaar; Matthias Samwald
Journal:  PLoS One       Date:  2022-06-08       Impact factor: 3.752

Review 4.  Translating pharmacogenomics into clinical decisions: do not let the perfect be the enemy of the good.

Authors:  Kristi Krebs; Lili Milani
Journal:  Hum Genomics       Date:  2019-08-27       Impact factor: 4.639

5.  Conference report: inaugural Pharmacogenomics Access & Reimbursement Symposium.

Authors:  Sara L Rogers; George P Patrinos; Christina Mitropoulou; Christine M Formea; J Shawn Jones; Benjamin G Brown
Journal:  Pharmacogenomics J       Date:  2021-06-17       Impact factor: 3.550

6.  Cost-effectiveness of precision medicine: a scoping review.

Authors:  Miriam Kasztura; Aude Richard; Nefti-Eboni Bempong; Dejan Loncar; Antoine Flahault
Journal:  Int J Public Health       Date:  2019-11-15       Impact factor: 3.380
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.